Indian drug major Sun pharmaceuticals has secured tentative approval from the United States Food and Drugs administration for the generic version of gleeven, used to treat chronic myeloid leukaemia. The drug will be available in two strengths of 100 mg and 400 mg and the market size for them is estimated at nearly $900 million.
crackcrack